Monthly Archives: May 2012

Pitt Men’s Study Flashback – Advertisements

Check out some of these advertisements from the old days that ran in Out Newspaper and other local publications. (Click to enlarge). on LogoTV’s Positive Youth, a social network for HIV+ men, featured on LogoTV’s ‘Positive Youth’ Documentary

Press release from LogoTV:

HIV+ Gay Men, confronting a common stigma, once found themselves socially isolated from the broader community. It is hard to make new friends and connections when the general public doesn’t understand the true nature of their affliction.

Seeing a great need for change, LogoTV featured in their new documentary ‘Positive Youth,’ which shines light on the hopeful reality of living HIV+ in 2012. Refusing to let the virus win, four inspirational HIV infected or affected young men and women interviewed in the film offer a raw, uncensored look into their daily lives: receiving an HIV diagnosis, positive/negative dating, the truth about medication and gaining the realization that life is not over and there is a future. – a community specifically constructed for HIV+ members in the English speaking world (e.g., Ireland, U.K., U.S., South Africa, New Zealand, Australia, and Canada) – is featured as a new place on the WWW proving to be a source of new friendships and emotional support for people who confront the daily ups and downs of living with HIV. The social network was deployed by Friend Factory – a niche social networking firm that has constructed and deployed communities for the wheelchair users, Latino and Deaf communities.

Where HIV+ people were previously restricted to making friends in and about their local communities or within organizations for their advocacy, allows these individuals to span oceans.

‘Positive Youth’ airs on LogoTV on Tuesday, June 19th and is currently available to stream online at

Media Contact:
Austin Head

HIV among Gay and Bisexual Men – Update from the CDC

From the CDC:

Gay, bisexual, and other men who have sex with men (MSM)1 represent approximately 2% of the US population, yet are the population most severely affected by HIV. In 2009, MSM accounted for 61% of all new HIV infections, and MSM with a history of injection drug use (MSM-IDU) accounted for an additional 3% of new infections. That same year, young MSM accounted for 69% of new HIV infections among persons aged 13–29 and 44% of infections among all MSM. At the end of 2009, an estimated 441,669 (56%) persons living with an HIV diagnosis in the US were MSM or MSM-IDU.

New HIV Infections

  • In 2009, MSM accounted for 61% of new HIV infections in the US and 79% of infections among all newly infected men. Compared with other groups, MSM accounted for the largest numbers of new HIV infections in 2009.
  • Among all MSM, white MSM accounted for 11,400 (39%) new HIV infections in 2009.  The largest number of new infections (3,400) occurred in those aged 40–49.
  • Among all MSM, black/African American MSM accounted for 10,800 (37%) new HIV infections in 2009. Whereas new HIV infections were relatively stable among MSM overall from 2006–2009, they increased 34% among young MSM—an increase largely due to a 48% increase among young black/African American MSM aged 13–29.
  • Among all MSM, Hispanic/Latino MSM accounted for 6,000 (20%) new HIV infections in 2009. The largest percentage of new infections (45%) occurred in those aged 13–29.

Estimates of New HIV Infections in the US, 2009, for the Most-Affected Subpopulations

Subpopulations representing 2% or less of the overall US epidemic are not reflected in this chart. Read more at the CDC’s Website, where you can downlaod their official report.

Drug moves toward FDA approval for HIV prevention

From the LA Times:

The Food and Drug Administration said Tuesday that Gilead Sciences’ Truvada appears to be safe and effective for HIV prevention. It concluded that taking the pill daily could spare users “infection with a serious and life-threatening illness that requires lifelong treatment.”

On Thursday, a panel of FDA advisors will vote on whether Truvada should be approved as a preventive treatment for people who are at high risk of contracting the human immunodeficiency virus through sexual intercourse. The FDA is not required to follow the advice of its panels, but usually does.

An estimated 1.2 million Americans have HIV, which attacks the immune system and, unless treated with antiviral drugs, develops into AIDS, a fatal condition in which the body cannot fight off infections. If Truvada is approved, it would be a major breakthrough in the 30-year campaign against the AIDS epidemic. No other drugs have been proven to prevent HIV and a vaccine is believed to be decades away.

Gilead Sciences Inc., based in Foster City, Calif., has marketed Truvada since 2004 as a treatment for people who are infected with the virus. The medication is a combination of two older HIV drugs, Emtriva and Viread. Doctors usually prescribe the medications as part of a drug cocktail that makes it harder for the virus to reproduce. Patients with low viral levels have reduced symptoms and are far less likely to develop AIDS.

Researchers first reported in 2010 that Truvada could prevent people from contracting HIV. A three-year study found that daily doses cut the risk of infection in healthy gay and bisexual men by 44%, when accompanied by condoms and counseling. Another study found that Truvada reduced infection by 75% in heterosexual couples in which one partner was infected with HIV and the other was not.

Read the full article on the LA Times Website.